NiCox SA completed the second leg of a two-part fundraising effort that has yielded gross proceeds of about €100 million (US$143.2 million), by raising €69.9 million in a discounted rights offering. The rights issue comprised 20,042,031 new shares, priced at €3.49 per share. The company's closing share price immediately before the Nov. 25 launch of the offer was €7.05, although it subsequently dropped well below that level. The stock closed Monday at €5.54. (BioWorld International) BioWorld International Correspondent 

Molecular Partners AG, which is commercializing a protein scaffold technology, raised CHF46 million (US$44.2 million) in a Series B financing round led by Essex Woodlands Health Ventures, taking its total investment raised in the past two and a half years to CHF64.5 million.(BioWorld International)